IKT News and Press, Inhibikase Therapeutics Inc. From 06/16/21

Inhibikase Therapeutics (IKT) -24% after prices stock offering at $3Blue Apron Holdings (APRN) -19% after announcing share offering.Alfi (ALF) -14%.Clearside Biomedical (CLSD) -10%.TAL Education (TAL) -10%.TDH Holdings (PETZ) -10%.Unique Fabricating (UFAB) -9%.Roblox (RBLX...

Inhibikase Therapeutics (IKT) has priced its public offering of 15M common shares at $3.00/share for total gross proceeds of ~$45M.Underwriters' over-allotment is an additional 2.25M shares. Net proceeds will be used for development of product candidates, for R&D activities, and other gen...

Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock PR Newswire ATLANTA , June 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify t...

Gainers: Enochian Biosciences ENOB +127%, RAPT Therapeutics RAPT +101%, iTeos Therapeutics ITOS +37%, Novan NOVN +30%, Anavex Life Sciences AVXL +23%.Losers: Avenue Therapeutics ATXI -39%, Inhibikase Therapeutics (IKT) -21%, ...

Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others PR Newswire ATLANTA , May 25, 2021 /PRNewswire/ -- Inhibika...

Inhibikase Therapeutics (IKT): Q1 GAAP EPS of -$0.26.Cash and cash equivalents were $9.6 million as of March 31, 2021.Press release. For further details see: Inhibikase Therapeutics reports Q1 results

Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity PR Newswire ATLANTA , May 17, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical co...

Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum PR Newswire ATLANTA , April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to ...

Inhibikase Therapeutics (IKT): Q4 GAAP EPS of -$0.15.Cash and cash equivalents of $13.95MPress Release For further details see: Inhibikase Therapeutics reports Q4 results

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity PR Newswire ATLANTA , April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company...